Team ImaginAb, our world-class radiopharmaceuticals team

At ImaginAb, everything we do is underpinned by medical expertise and scientific innovation. And our people are paramount to that.

Leading the next phase of our biotech and pharmaceutical advances is a strong team of scientists and business experts with unique skills and industry accolades.

Read on to discover more about them and how they’re striving to create, challenge and transform the future of immuno oncology patient care paths, helping patients to live better and healthier lives.

Management Team

Ian Wilson

Chief Executive Officer

David Fractor

Chief Financial Officer

Gareth Smith

General Manager – Europe

Ron Korn

Chief Medical Imaging Officer

William Le

VP, Operations

Our Team

Argin Aivazian

Associate, Scientist of Assay Development

Clinique Burrell

Administrative Manager

Kathleen Brady

Quality Assurance Manager

Maria Corsi

Clinical Research Associate

Jenny Crager

Project Co-ordinator, R&D

Kelley Diaz

Principal Scientist in-vivo Biologist

Jill Durkin

Controller

Matthew Ennis

Director, Business Development

Michael Ferris

Project Manager

Gregory Frank

Director, Business Development

Fang Jia

Associate Director, Chemistry

Patrick Joyce

Principal Research Scientist

Alessandro Mascioni

Director, Research

Nadine Richter

Accounting Manager

Jim Sindelar

QA Specialist

Leticia Maria de Souza Cordeiro

Principal Scientist in-vivo Biologist

Elizabeth Thomas

Associate Director, Regulatory Affairs

Katherine Young

Clinical Trial Manager

Board of Directors

Anna M. Wu

Founder and Chief Scientific Advisor

Friedhelm Blobel

Independent Non-Executive Director

Tim Irish

Independent Non-Executive Director

Jules Haimovitz

Member of the Board

Scientific Advisory Board

James P. Allison

Scientific Advisor

Jeffrey L. Evelhoch

Scientific Advisor

Daniel D. Von Hoff

Scientific Advisor

David Mankoff

Scientific Advisor

Antoni Ribas

Scientific Advisor

Padmanee Sharma

Scientific Advisor


Join us to reimagine the future of immuno oncology.